Table 1.
Characteristics of the included randomized controlled trials
| study ID | blinding, type of control |
gender of participants |
age range |
N | duration of trial (weeks) |
primary antipsychotic medication(s) used |
daily dosage of aripiprazole |
|---|---|---|---|---|---|---|---|
| Xu 2006[24] | single-blind, placebo-control |
female | 18-35 | 60 | 6 | risperidone, sulpiride |
5mg |
| Shim 2007[18] | double-blind, placebo-control |
both genders | 18-45 | 54 | 8 | haloperidol | 15mg-30mg |
| Zhang 2008[38] | single-blind, placebo-control |
both genders | 25-52 | 60 | 6 | perphenazine | 5mg |
| Ji 2008[39] | single-blind, placebo-control |
female | 18-35 | 117 | 6 | risperidone | 5mg |
| Jin 2008[40] | blinding not specified, placebo-control |
both genders | 18-52 | 80 | 6 | chlorpromazine | 5mg |
| Chen 2009[20] | double-blind, placebo-control |
male | 18-50 | 72 | 8 | risperidone | 5mg |
| Kane 2009[19] | double-blind, placebo-control |
both genders | >18 | 252 | 16 | risperidone, quetiapine |
10mg |
| Wang 2009[41] | single-blind, placebo-control |
female | not specified |
60 | 6 | haloperidol | 5mg |
| Song 2009[42] | single-blind, placebo-control |
both genders | 18-35 | 140 | 6 | sulpiride | 5mg |
| Chen 2010[21] | single-blind, placebo-control |
male | not specified |
60 | 8 | sulpiride | 5mg |
| Liu (L) 2011[43] | blinding not specified, placebo-control |
both genders | 18-45 | 86 | 4 | risperidone | 5mg-10mg |
| Liu (Z) 2011[44] | blinding not specified, no-treatment control |
both genders | 18-70 | 180 | 26 | risperidone, clozapine, perphenazine, chlorpromazine |
5mg |
| Sun 2011[45] | blinding not specified, no-treatment control |
female | 18-45 | 56 | 12 | olanzapine | 10mg |
| Xue 2012[46] | single-blind, placebo-control |
male | not specified |
68 | 6 | risperidone | 5mg |
| Zhou 2012[47] | single-blind, placebo-control |
female | 18-45 | 60 | 12 | risperidone | 10mg |
| Zhu 2012[48] | single-blind, placebo-control |
female | 18-60 | 65 | 8 | risperidone | 5mg |
| Wu 2013[49] | blinding not specified, no-treatment control |
both genders | >60 | 63 | 12 | risperidone, sulpiride, perphenazine, chlorpromazine |
5mg |
| Guo 2013[50] | blinding not specified, no-treatment control |
female | 18-45 | 86 | 12 | risperidone, sulpiride, perphenazine, chlorpromazine |
5mg |
| Chen 2014[27] | double-blind, placebo-control |
both genders | 18-45 | 116 | 8 | risperidone | 20mg |
| Pan 2014[51] | blinding not specified, placebo-control |
female | 18-52 | 58 | 6 | risperidone, sulpiride |
10mg |
| Qiao 2015[52] | blinding not specified, no-treatment control |
female | 18-45 | 60 | 8 | risperidone, paliperidone |
5mg |